AZN Stock Recent News
AZN LATEST HEADLINES
Some employees of British pharmaceutical giant AstraZeneca have been detained by police in China as part of an investigation, the company confirmed Thursday. "We are aware a small number of our employees in China are under investigation and we have no further information to share at this point," an AstraZeneca spokesperson told CNBC by email.
The police in China have detained five current and former employees of AstraZeneca for questioning about potential illegal activities, Bloomberg News reported on Thursday, citing people familiar with the matter.
QGEN's expanded collaboration with AstraZeneca to focus on developing companion diagnostics beyond oncology.
AstraZeneca (LON: AZN) share price is firing on all cylinders as it sits on its all-time high. It has soared in the last five consecutive weeks, the longest streak since April 2023.
New agreement expands collaboration with AstraZeneca beyond oncology, including complex chronic diseases // QIAGEN's syndromic testing platform QIAstat-Dx enables specialty care providers to make fast decisions about patients' eligibility for investigational precision medicines New agreement expands collaboration with AstraZeneca beyond oncology, including complex chronic diseases // QIAGEN's syndromic testing platform QIAstat-Dx enables specialty care providers to make fast decisions about patients' eligibility for investigational precision medicines
AstraZeneca has warned it could relocate its vaccine manufacturing site from the UK to the U.S. amid a deadlock in negotiations with the Labour government over plans to cut state aid promised to the project, the Financial Times reported on Thursday.
In the ever-evolving pharmaceutical landscape, financial stability and business resilience are crucial for long-term success. S&P Global, a leading financial information firm, recently released a comprehensive report evaluating the world's top pharmaceutical companies based on their business and financial risk profiles.
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU® Granted Breakthrough Therapy Designation in U.S. for Certain Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer.
This approval is based on late-stage study data, which shows that treatment with AstraZeneca's (AZN) Imfinzi reduced the risk of recurrence by 32% in certain non-small cell lung cancer patients.
AstraZeneca PLC's (LSE:AZN) blockbuster immunotherapy cancer drug Imfinzi (durvalumab) has received another approval in the US. In combination with chemotherapy, patients suffering resectable early-stage (IIA-IIIB) non-small cell lung cancer (NSCLC) can now receive Imfinzi before and after surgery.